DGIdb - PALBOCICLIB Drug Record

PALBOCICLIB chembl:CHEMBL189963 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PD-0332991
PALBOCICLIB
IBRANCE
UNII-G9ZF61LE7G
PD 332991
IBRANCE®
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
PD 0332991
PD0332991
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE
rxcui:1601374
chemidplus:571190-30-2
chembl:CHEMBL189963
pubchem.compound:5330286
drugbank:09073

Drug Info:

Drug Categories	cyclin-dependent kinases, antagonists & inhibitors
Drug Class	Kinase Inhibitors
FDA Approval	Breast cancer (HR+, HER2-)
Drug Class	Small molecule inhibitor
Pharmaceutical Developer	Pfizer
Source Reported Drug Name(s)	PD0332991
Drug Class	CDK/Rb Inhibitor
Drug Groups	investigational
Drug Categories	bcrp/abcg2 inhibitors
Drug Categories	bcrp/abcg2 substrates
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	kinase inhibitor
Drug Categories	narrow therapeutic index drugs
Drug Categories	oct1 inhibitors
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates

(13 More Sources)

Publications:

Rocca A et al., 2017, Progress with palbociclib in breast cancer: latest evidence and clinical considerations., Ther Adv Med Oncol
Fry et al., 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts., Mol. Cancer Ther.
Finn et al., 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study., Lancet Oncol.
Gao et al., 2015, Does CDKN2A loss predict palbociclib benefit?, Curr Oncol
Konecny et al., 2011, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer., Clin. Cancer Res.
Cen et al., 2012, p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells., Neuro-oncology
Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.
Katsumi et al., 2011, Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression., Biochem. Biophys. Res. Commun.
Young et al., 2014, Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines., Pigment Cell Melanoma Res
Forbes et al., 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer., Nucleic Acids Res.
Kwong et al., 2012, Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma., Nat. Med.
Perez et al., 2015, Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA., Oncotarget
Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget
Huang et al., 2015, CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation., Int J Clin Exp Med
von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.
Logan et al., 2013, PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity., Anticancer Res.
Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.
Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol
Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem
Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
Ziemke et al., 2016, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6., Clin. Cancer Res.
Finn et al., 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro., Breast Cancer Res.
Witkiewicz et al., 2014, CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models., Genes Cancer
Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood
Taylor-Harding B et al., 2015, Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS., Oncotarget
Turner NC et al., 2019, Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer., J Clin Oncol
Hanaford et al., 2016, DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets., Clin. Cancer Res.
Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol
Dean et al., 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure., Oncogene
Schröder et al., 2015, CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?, Front Oncol
Michaud et al., 2010, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts., Cancer Res.
Sawai et al., 2012, Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia., Cancer Cell
Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
Lee et al., 2016, Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models., Oncotarget
Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun

PALBOCICLIB CDKN2B

Interaction Score: 2.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23898052

Sources:
CIViC
PALBOCICLIB CCNE1

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25557169 27020857 30807234

Sources:
CIViC
PALBOCICLIB CDKN2A

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + Trametinib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
26715889 21278246 22711607 27488531 21871868 24495407 20952405 22983396 26528855 25156567 26380006 26183925 23898052

Sources:
OncoKB JAX-CKB CIViC
PALBOCICLIB CCND3

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23079656

Sources:
CIViC
PALBOCICLIB CDK4

Interaction Score: 0.62

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction CDK4/cyclin D1 inhibitor

Direct Interaction yes

PMIDs:
28203301 25810375 23569312 27124835 26528855 23898052 24417566 15542782

Sources:
CancerCommons MyCancerGenomeClinicalTrial DTC OncoKB CIViC DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
PALBOCICLIB RB1

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family CDK4/6 inhibitor

Alteration RB1:over

Indication/Tumor Type glioblastoma multiforme

PMIDs:
27012813 29236940 22711607 20473330 27020857 26649278 27488531 20354191

Sources:
JAX-CKB CIViC CGI
PALBOCICLIB SMARCA4

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30718512 30718506

Sources:
CIViC
PALBOCICLIB CDK6

Interaction Score: 0.51

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
28203301 15542782

Sources:
CancerCommons MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
PALBOCICLIB CCND2

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family CDK4/6 inhibitor

Alteration CCND2:amp

PMIDs:
None found

Sources:
CGI
PALBOCICLIB SMARCB1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type rhabdoid cancer

Response Type decreased response

Approval Status Preclinical

PMIDs:
21871868

Sources:
JAX-CKB
PALBOCICLIB CCND1

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CDK6/cyclin D1 inhibitor

Direct Interaction yes

PMIDs:
24417566

Sources:
DTC ChemblInteractions
PALBOCICLIB DYRK1B

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PRKX

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB NRAS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27488531 22983396

Sources:
JAX-CKB
PALBOCICLIB NEK2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB KRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
1291017 26658964 26369631 27167191

Sources:
JAX-CKB CIViC CGI
PALBOCICLIB PAK4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB DAPK3

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ERBB2:norm;ESR1:over

Drug family CDK4/6 inhibitor

combination therapy Palbociclib + Trastuzumab

PMIDs:
27020857 19874578 25221644

Sources:
FDA PharmGKB JAX-CKB CGI
PALBOCICLIB DYRK1A

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB CLK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB LRRK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB CDK9

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MST1R

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MAP4K2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PRKAA1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PIK3CA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type no benefit

Approval Status Preclinical

PMIDs:
27020857 25002028 26369631

Sources:
JAX-CKB CIViC
PALBOCICLIB TAOK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB BRAF

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27488531 26369631

Sources:
JAX-CKB
PALBOCICLIB MAP4K5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MAPK9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB RPS6KA3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PRKD3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB ROCK2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MAP4K4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB MAPK8

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB FLT3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + Tandutinib

combination therapy Palbociclib + SGI-1776

combination therapy Palbociclib + Quizartinib

PMIDs:
27099147

Sources:
JAX-CKB
PALBOCICLIB CDK5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB
PALBOCICLIB ESR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family CDK4/6 inhibitor

Alteration ERBB2:norm;ESR1:over

PMIDs:
25524798

Sources:
FDA PharmGKB CIViC CGI
PALBOCICLIB CLK4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB CHEK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB ALK

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB RET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PALBOCICLIB PGR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PALBOCICLIB ESR2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PALBOCICLIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB09073

Version: 5.1.7

Alternate Names:

PALBOCICLIB DrugBank Drug Name

571190-30-2 CAS Number

Ibrance Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Rocca A et al., 2017, Progress with palbociclib in breast cancer: latest evidence and clinical considerations., Ther Adv Med Oncol

Fry et al., 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts., Mol. Cancer Ther.

MyCancerGenome: PALBOCICLIB
- Version: 20-Jun-2017
Alternate Names:

IBRANCE Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Breast cancer (HR+, HER2-)

Publications:
CancerCommons: PALBOCICLIB
- Version: 25-July-2013
Alternate Names:

PD 0332991 PubChem Drug Name

11431660 PubChem Drug ID

Palbociclib Drug Trade Name

Drug Info:

Drug Class CDK/Rb Inhibitor

Source Reported Drug Name(s) PD0332991

Pharmaceutical Developer Pfizer

Publications:
MyCancerGenome: PD0332991
- Version: 20-Jun-2017
Alternate Names:

PD0332991 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

DTC: PALBOCICLIB

Version: 02-September-2020

Alternate Names:

CHEMBL189963 ChEMBL Drug ID

Drug Info:

Publications:

Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem

JAX-CKB: Palbociclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.

Ziemke et al., 2016, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6., Clin. Cancer Res.

Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.

CGI: Palbociclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.

Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov

JAX-CKB: PD0332991
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget

CIViC: PALBOCICLIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res

Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.

Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol

GuideToPharmacology: 178103952
- Version: 29-September-2020
Alternate Names:

PALBOCICLIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL189963
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: PD-0332991
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
CGI: PD-0332991
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
OncoKB: Palbociclib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
PharmGKB: palbociclib
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL189963
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Palbociclib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

combination therapy	Palbociclib + Trametinib
Indication/Tumor Type	melanoma
Response Type	sensitive

Reported Cancer Type	Melanoma
Mechanism of Interaction	CDK4/cyclin D1 inhibitor
Direct Interaction	yes

Drug family	CDK4/6 inhibitor
Alteration	RB1:over
Indication/Tumor Type	glioblastoma multiforme

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Indication/Tumor Type	rhabdoid cancer
Response Type	decreased response
Approval Status	Preclinical

Mechanism of Interaction	CDK6/cyclin D1 inhibitor
Direct Interaction	yes

Alteration	ERBB2:norm;ESR1:over
Drug family	CDK4/6 inhibitor
combination therapy	Palbociclib + Trastuzumab

Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	no benefit
Approval Status	Preclinical

combination therapy	Palbociclib + Tandutinib
combination therapy	Palbociclib + SGI-1776
combination therapy	Palbociclib + Quizartinib

combination therapy	Palbociclib + GDC-0941
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	no benefit

PALBOCICLIB	DrugBank Drug Name
571190-30-2	CAS Number
Ibrance	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

PD 0332991	PubChem Drug Name
11431660	PubChem Drug ID
Palbociclib	Drug Trade Name

PALBOCICLIB Drug Record

PALBOCICLIB chembl:CHEMBL189963 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23898052

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25557169 27020857 30807234

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Palbociclib + Trametinib Indication/Tumor Type melanoma Response Type sensitive

PMIDs: 26715889 21278246 22711607 27488531 21871868 24495407 20952405 22983396 26528855 25156567 26380006 26183925 23898052

Sources: OncoKB JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23079656

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Reported Cancer Type Melanoma Mechanism of Interaction CDK4/cyclin D1 inhibitor Direct Interaction yes

PMIDs: 28203301 25810375 23569312 27124835 26528855 23898052 24417566 15542782

Sources: CancerCommons MyCancerGenomeClinicalTrial DTC OncoKB CIViC DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Drug family CDK4/6 inhibitor Alteration RB1:over Indication/Tumor Type glioblastoma multiforme

PMIDs: 27012813 29236940 22711607 20473330 27020857 26649278 27488531 20354191

Sources: JAX-CKB CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30718512 30718506

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: 28203301 15542782

Sources: CancerCommons MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Drug family CDK4/6 inhibitor Alteration CCND2:amp

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type rhabdoid cancer Response Type decreased response Approval Status Preclinical

PMIDs: 21871868

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CDK6/cyclin D1 inhibitor Direct Interaction yes

PMIDs: 24417566

Sources: DTC ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 27488531 22983396

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Palbociclib + Trametinib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 1291017 26658964 26369631 27167191

Sources: JAX-CKB CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Alteration ERBB2:norm;ESR1:over Drug family CDK4/6 inhibitor combination therapy Palbociclib + Trastuzumab

PMIDs: 27020857 19874578 25221644

Interaction Types & Directionality:

n/a

PMIDs:
23898052

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25557169 27020857 30807234

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + Trametinib

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
26715889 21278246 22711607 27488531 21871868 24495407 20952405 22983396 26528855 25156567 26380006 26183925 23898052

Sources:
OncoKB JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
23079656

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Melanoma

Mechanism of Interaction CDK4/cyclin D1 inhibitor

Direct Interaction yes

PMIDs:
28203301 25810375 23569312 27124835 26528855 23898052 24417566 15542782

Sources:
CancerCommons MyCancerGenomeClinicalTrial DTC OncoKB CIViC DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family CDK4/6 inhibitor

Alteration RB1:over

Indication/Tumor Type glioblastoma multiforme

PMIDs:
27012813 29236940 22711607 20473330 27020857 26649278 27488531 20354191

Sources:
JAX-CKB CIViC CGI

Interaction Types & Directionality:

n/a

PMIDs:
30718512 30718506

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
28203301 15542782

Sources:
CancerCommons MyCancerGenomeClinicalTrial DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family CDK4/6 inhibitor

Alteration CCND2:amp

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type rhabdoid cancer

Response Type decreased response

Approval Status Preclinical

PMIDs:
21871868

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CDK6/cyclin D1 inhibitor

Direct Interaction yes

PMIDs:
24417566

Sources:
DTC ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
27488531 22983396

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
1291017 26658964 26369631 27167191

Sources:
JAX-CKB CIViC CGI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ERBB2:norm;ESR1:over

Drug family CDK4/6 inhibitor

combination therapy Palbociclib + Trastuzumab

PMIDs:
27020857 19874578 25221644

Sources:
FDA PharmGKB JAX-CKB CGI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a